4-aminoquinoline (antimalarial / DMARD)
Hydroxychloroquine
Weak-base lysosomotropic agent that raises endosomal pH, interfering with antigen processing and Toll-like- signalling, with additional effects on .
Primary Mechanism of Action
Clinical / Scientific
As a weak base, hydroxychloroquine accumulates in acidic vesicles, raising pH. This impairs endosomal antigen processing, nucleic-acid sensing via TLR7/9, and autophagosome–lysosome fusion. Antimalarial activity against blood-stage Plasmodium is a separate, established use of the 4-aminoquinoline class.
Pathway Targets
Endosomal TLR signalling
Scientific explanation
Reduced TLR7/9 activation after vesicle alkalinization.
Autophagy
Scientific explanation
Impaired autophagosome–lysosome fusion.
Antigen presentation
Scientific explanation
Altered MHC class II processing in antigen-presenting cells.
Pathway Convergence
Clinical / Scientific
Target → pathway → downstream effect → biological consequence. This is a mechanistic map, not a treatment claim.
Innate immune dampening
Target to downstream effect: Lysosomal alkalinization → Reduced TLR7/9 signalling → Lower type-I interferon and inflammatory output in some settings
Mechanistically Relevant Repurposed & Adjunctive Applications
Malaria and labelled autoimmune disease
EstablishedMechanistic rationale
Established for labelled antimalarial and rheumatologic indications (for example SLE, RA) per regional prescribing information.
Antiviral endosomal entry hypotheses
InvestigationalMechanistic rationale
Endosomal pH effects were investigated for some viral entry pathways. Clinical efficacy is disease-specific and must not be generalized from mechanism alone.
Mechanistic Application Matrix
| Biological Target | Mechanism | Potential Relevance | Evidence Level |
|---|---|---|---|
| TLR7/9 | Endosomal pH-dependent suppression | Innate nucleic-acid sensing | Established mechanism |
| Autophagy | Fusion impairment | Vesicular trafficking | Established mechanism |
Mechanistic Interaction Considerations
QT prolongation, retinopathy with long-term use, and hypoglycaemia are labelled risks. Combining with other QT-prolonging or hypoglycaemic agents requires clinical judgement.
In Plain Language
Hydroxychloroquine collects in the cell’s acidic compartments and makes them less acidic. That change can slow some immune “alarm” pathways that start inside those compartments.
Oncology Mechanistic Relevance
Cancers in the atlas where this compound has a mapped mechanistic rationale. Evidence tiers are not equivalent and do not imply treatment.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Lysosomal pH elevation impairs flux. Early combination trials exist; benefit is not established and toxicity/retinal risk remain labelled concerns.
Mechanistic information is provided for scientific and educational purposes. Discussion of biological pathways or investigational applications does not establish clinical efficacy or constitute individualized medical advice.